CY1110017T1 - Μικρονισμενη ταναπρογετη και συνθεσεις που περιεχουν αυτην - Google Patents

Μικρονισμενη ταναπρογετη και συνθεσεις που περιεχουν αυτην

Info

Publication number
CY1110017T1
CY1110017T1 CY20101100393T CY101100393T CY1110017T1 CY 1110017 T1 CY1110017 T1 CY 1110017T1 CY 20101100393 T CY20101100393 T CY 20101100393T CY 101100393 T CY101100393 T CY 101100393T CY 1110017 T1 CY1110017 T1 CY 1110017T1
Authority
CY
Cyprus
Prior art keywords
compositions
magnesium stearate
microcrystalline cellulose
croscarmellose sodium
contain microcrystalline
Prior art date
Application number
CY20101100393T
Other languages
English (en)
Inventor
Arwinder Nagi
Ramarao Chatlapalli
Shamim Hasan
Rolland W Carson
Mohamed Ghorab
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of CY1110017T1 publication Critical patent/CY1110017T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fertilizers (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει συνθέσεις, επιθυμητά φαρμακευτικές συνθέσεις περιέχουσες μικρονισμένη ταναπρογέτη. Οι συνθέσεις μπορεί επίσης να περιέχουν μικροκρυσταλλική κυτταρίνη, μετά νατρίου croscarmellose, άνυδρη λακτόζη και στεατικό μαγνήσιο ή μπορεί να περιέχουν μικροκρυσταλλική κυτταρίνη, μετά νατρίου croscarmellose, λαουρύλ θειικό νάτριο, povidone και στεατικό μαγνήσιο. Οι συνθέσεις είναι χρήσιμες στη θεραπεία αντισύλληψης και τη θεραπεία αντικατάστασης ορμόνης και στη θεραπεία ή/και την πρόληψη μυομητρικών ινωμάτων της μήτρας, καλοήθους προστατικής υπερτροφίας, καλοήθους και κακοήθους νεοπλασματικής νόσου, δυσλειτουργικής αιμορραγίας, λειομυομάτων μήτρας, ενδομητρίωσης, συνδρόμου πολυκυστικής ωοθήκης και καρκινωμάτων και αδενοκαρκινωμάτων της υπόφυσης, ενδομητρίου, νεφρού, ωοθήκης, μαστού, κόλον και προστάτη και άλλων ορμονο-εξαρτώμενων όγκων και στην παρασκευή φαρμάκων χρήσιμων για αυτούς. Επιπρόσθετες χρήσεις περιλαμβάνουν διέγερση πρόσληψης τροφής.
CY20101100393T 2005-04-28 2010-05-05 Μικρονισμενη ταναπρογετη και συνθεσεις που περιεχουν αυτην CY1110017T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67555105P 2005-04-28 2005-04-28
EP06751636A EP1877059B8 (en) 2005-04-28 2006-04-26 Micronized tanaproget and compostions containing same

Publications (1)

Publication Number Publication Date
CY1110017T1 true CY1110017T1 (el) 2015-01-14

Family

ID=37027926

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100393T CY1110017T1 (el) 2005-04-28 2010-05-05 Μικρονισμενη ταναπρογετη και συνθεσεις που περιεχουν αυτην

Country Status (17)

Country Link
US (3) US20060246128A1 (el)
EP (1) EP1877059B8 (el)
JP (3) JP5149160B2 (el)
CN (1) CN101166533A (el)
AT (1) ATE461701T1 (el)
AU (1) AU2006239284C1 (el)
BR (1) BRPI0610431A2 (el)
CA (1) CA2603594C (el)
CY (1) CY1110017T1 (el)
DE (1) DE602006013114D1 (el)
DK (1) DK1877059T3 (el)
ES (1) ES2340518T3 (el)
MX (1) MX2007013467A (el)
PL (1) PL1877059T3 (el)
PT (1) PT1877059E (el)
SI (1) SI1877059T1 (el)
WO (1) WO2006116596A2 (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1175411B1 (en) * 1999-05-04 2008-02-20 Wyeth Cyclothiocarbamate derivatives as progesterone receptor modulators
CA2603817C (en) 2005-04-28 2013-03-19 Wyeth Compositions containing micronized tanaproget prepared by wet granulation
CN101166736B (zh) * 2005-04-28 2013-02-06 惠氏公司 他那普戈特的多晶型ⅱ
MX2007013465A (es) * 2005-04-28 2008-01-21 Wyeth Corp Tanaproget micronizado, composiciones y metodos para preparar las mismas.
CA2603594C (en) * 2005-04-28 2013-11-05 Wyeth Micronized tanaproget and compositions containing same
AU2006258048A1 (en) 2005-06-09 2006-12-21 Wyeth Tanaproget compositions containing ethinyl estradiol
JP2011507853A (ja) * 2007-12-20 2011-03-10 テバ ウィメンズ ヘルス インコーポレイテッド 緊急避妊のための投与量レジメンならびに薬学的組成物およびパッケージ
US8512745B2 (en) 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
SG175314A1 (en) 2009-04-24 2011-11-28 Iceutica Pty Ltd A novel formulation of diclofenac
US9326997B2 (en) 2012-09-24 2016-05-03 Ahlam E. Elakkad Composition and method for treation Oligoovulation, Oligomenorrhea and Amenorrhea
SG10201913076PA (en) * 2013-12-12 2020-02-27 Almirall Sa Pharmaceutical compositions comprising dimethyl fumarate
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
PT3892302T (pt) 2015-04-06 2023-11-15 Janssen Pharmaceutica Nv Composições que contêm ibrutinib
KR102305932B1 (ko) 2015-06-29 2021-09-28 플로로놀 인코퍼레이티드 갈조류의 고체 약제학적 조성물
CN110636838A (zh) 2017-06-23 2019-12-31 阿尔米雷尔有限公司 包含反丁烯二酸二甲酯的药物组合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2006A (en) * 1841-03-16 Clamp for crimping leather
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
EP1175411B1 (en) * 1999-05-04 2008-02-20 Wyeth Cyclothiocarbamate derivatives as progesterone receptor modulators
US6423699B1 (en) * 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6544553B1 (en) * 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US6962908B2 (en) * 2001-12-21 2005-11-08 Warner Chilcott Company Inc. Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
EP1531824A4 (en) 2002-06-25 2005-09-21 Wyeth Corp CYCLOTHIOCARBAMATIVE DERIVATIVES AS PR MODULATORS AND THEIR USE IN TREATING SKIN DISORDERS
AR040333A1 (es) * 2002-06-25 2005-03-30 Wyeth Corp Uso de derivados de ciclotiocarbamatos en el tratamiento de condiciones relacionadas con hormonas
US8404272B2 (en) * 2003-06-26 2013-03-26 Poly-Med, Inc. Fiber-reinforced composite rings for intravaginal controlled drug delivery
PA8631101A1 (es) 2004-04-27 2006-09-08 Wyeth Corp Proceso de acoplamiento para la generacion de derivados reactivos de pirrol-2-carbonitrilo n-sustituidos con contenido de boro para producir biarilos
US7514466B2 (en) * 2004-04-27 2009-04-07 Wyeth Purification of progesterone receptor modulators
ATE396189T1 (de) * 2004-04-27 2008-06-15 Wyeth Corp Cyanopyrrolhaltige cyclische carbamat- und thiocarbamatbiaryle und verfahren zu deren herstellung
TW200603813A (en) * 2004-07-07 2006-02-01 Wyeth Corp Cyclic progestin regimens and kits
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200500183A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
AU2005272854B2 (en) * 2004-08-13 2012-04-26 Wyeth Tanaproget derivatives, metabolites, and uses thereof
AU2005285355A1 (en) * 2004-08-20 2006-03-23 Wyeth Progesterone receptor structure
CA2603594C (en) * 2005-04-28 2013-11-05 Wyeth Micronized tanaproget and compositions containing same
MX2007013465A (es) * 2005-04-28 2008-01-21 Wyeth Corp Tanaproget micronizado, composiciones y metodos para preparar las mismas.
EP1874743B1 (en) * 2005-04-28 2013-07-17 Wyeth LLC Purified form of tanaproget
CA2603817C (en) * 2005-04-28 2013-03-19 Wyeth Compositions containing micronized tanaproget prepared by wet granulation
CN101166736B (zh) * 2005-04-28 2013-02-06 惠氏公司 他那普戈特的多晶型ⅱ
AU2006258048A1 (en) * 2005-06-09 2006-12-21 Wyeth Tanaproget compositions containing ethinyl estradiol

Also Published As

Publication number Publication date
DK1877059T3 (da) 2010-05-31
SI1877059T1 (sl) 2010-07-30
MX2007013467A (es) 2008-01-21
PL1877059T3 (pl) 2010-07-30
ES2340518T3 (es) 2010-06-04
JP5149160B2 (ja) 2013-02-20
BRPI0610431A2 (pt) 2012-10-23
JP2008539262A (ja) 2008-11-13
AU2006239284A1 (en) 2006-11-02
WO2006116596A3 (en) 2006-12-14
JP2012255000A (ja) 2012-12-27
US20110091539A1 (en) 2011-04-21
US20060246128A1 (en) 2006-11-02
CA2603594C (en) 2013-11-05
CA2603594A1 (en) 2006-11-02
US8513240B2 (en) 2013-08-20
AU2006239284C1 (en) 2011-07-28
PT1877059E (pt) 2010-05-04
ATE461701T1 (de) 2010-04-15
AU2006239284B2 (en) 2011-03-31
EP1877059A2 (en) 2008-01-16
US20130337058A1 (en) 2013-12-19
EP1877059B1 (en) 2010-03-24
WO2006116596A2 (en) 2006-11-02
CN101166533A (zh) 2008-04-23
EP1877059B8 (en) 2010-05-19
DE602006013114D1 (de) 2010-05-06
JP2014205684A (ja) 2014-10-30

Similar Documents

Publication Publication Date Title
CY1110017T1 (el) Μικρονισμενη ταναπρογετη και συνθεσεις που περιεχουν αυτην
TW200716129A (en) Micronized tanaproget, compositions, and methods of preparing the same
DK1874278T3 (da) Sammensætninger indeholdende mikroniseret tanaproget
TW200716621A (en) Polymorph form II of tanaproget
TW200731969A (en) Use of progesterone receptor modulators
Engel et al. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone
CY1121926T1 (el) (11.βητα., 17.βητα.)-17-υδροξυ-11-[4(μεθυλοσουλφονυλο)φαινυλο]-17-(πενταφθορομεθυλο)οιστρα-4,9-διεν-3-ονη για την αγωγη παθησεων
BR0006265A (pt) Composto de tetrahidroisoquinolinas como agonistas/antagonistas de estrogênios
CY1106610T1 (el) Μεθοδος για την προληψη ή την θεραπευτικη αντιμετωπιση καλοηθων γυναικολογικων διαταραχων
IN2012DN05078A (el)
RU2016119135A (ru) Производные пиразолопиримидона или пирролотриазона, способ их получения и их фармацевтические применения
EA201491344A1 (ru) Производные спироиндолина в качестве антагонистов рецептора гонадотропин-рилизинг гормона
ATE515493T1 (de) Mercaptophenylnaphthylmethan-derivate und deren herstellung
AU2003255820A8 (en) Derivatives of 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazole as antagonists of the gonadotropin releasing hormone (gnrh) for use in the treatment of sex hormone related conditions, such as prostatic of uterine cancer
DE602005019905D1 (de) -modulatoren
NZ515353A (en) Cyclothiocarbamate derivatives as progesterone receptor modulators
ATE512985T1 (de) Diagnostische und therapeutische anwendungen von löslichem lhcgr-protein
CY1109919T1 (el) Παραγωγα της ινδολης που ειναι χρησιμα σα ρυθμιστες του υποδοχεα της προγεστερονης
ATE275973T1 (de) Empfängnisverhütende zusammensetzungen die progestagen und progesteronantagonisten enthalten
MX2009009515A (es) Cianopirrol sulfonamidas utiles para la modulacion del receptor de progesterona.
EA201501000A1 (ru) Спироиндолиновые производные для применения в качестве антагонистов рецептора гонадотропин-рилизинг-гормона
TH58099B (th) การใช้ และสารผสมแอนติโปรเจสตินในการรักษาโรคต่อมลูกหมาก
WO2008112498A3 (en) Synthesis and characterization of polymorph form ii of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile
AR023854A1 (es) Uso de derivados de indolina y equipo farmaceutico para regimenes ciclicos